Navigation Links
Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
Date:7/15/2008

- Company Reports Favorable Phase 1 RX-3341 Results -

NEW HAVEN, Conn., July 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the initiation of a Phase 2 clinical trial for an intravenous form of antibiotic compound RX-3341 in the treatment of complicated skin and skin structure infections (cSSSIs). The safety and efficacy study will be conducted at 35 sites across the United States. As a precursor to this news the Company also announced positive results of a two-part Phase 1 study with the same candidate.

"We have made significant progress in advancing this next-generation broad spectrum antibiotic further toward clinical use," said Dr. Susan Froshauer, President and CEO of Rib-X. "We intend to rapidly move forward with the development of our IV dosage form to meet the need for a broad-spectrum antibiotic in the hospital setting, particularly one that is active against quinolone-resistant MRSA. We also hope to further progress our oral dosage form to ensure a greater diversity of use in the treatment of serious infections in a number of settings."

Phase 2 Study Design

This Phase 2 double-blind study (study RX-3341-201) will evaluate the safety and efficacy of RX-3341 at two different doses administered intravenously to hospitalized cSSSI patients every 12 hours for 5 to 14 days, as compared to tigecycline (Tygacil(TM)). The study's primary endpoint is the assessment of RX-3341 efficacy, safety and tolerability at the two different doses compared to that of tigecycline's standard dosing regimen. A secondary endpoint for the study is the assessment of clinical efficacy of RX-3341 compared to tigecycline in patients with cSSSIs caused by methicillin- resistant Staphylococcus aureus (MRSA).

Phase I Results

The two-part Phase 1 stud
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
2. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
3. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
4. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
5. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
6. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
7. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
8. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. Isis Pharmaceuticals Conference Call Notice
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... TORONTO , May 22, 2013  Medifocus, ... John Mon , Chief Operating Officer, will present ... May 30, 2013 in New York City ... Company,s presentation is scheduled to begin at 4:00 p.m. EDT ... the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   For ...
(Date:5/22/2013)... , May 22, 2013 While many ... teens, friends to drink at home under adult supervision ... drinking, the truth is that there are serious negative ... at Drugfree.org and The Treatment Research Institute ... interactive web resource for parents and caregivers to help ...
(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013  OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...
Breaking Medicine Technology:Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 2Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 3Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 4Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 5Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 6Myths Debunked: Underage Drinking of Alcohol at Home Leads to Real Consequences for Both Parents and Teens 7OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5
... For more information, please go to: http://monistat.presslift.com/yeastinfections ... never suffered from the uncomfortable symptoms of a yeast ... women will experience their first yeast infection before age ... highest among young women ages 18-24 (2), who are ...
... 8 Regenicin™ (OTC Bulletin Board: ... to restore the qualities of healthy human skin, will present ... New York Palace Hotel, New York City from September 12-15, ... Wednesday, September 15th at 11:15 am EDT to provide a ...
Cached Medicine Technology:Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections 2Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections 3Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections 4Regenicin™ to Present at the Rodman & Renshaw Healthcare Conference 2
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Roughly four in ... obstructive pulmonary disease (COPD) actually do not have the ... issue: Faulty diagnoses were made based on an evaluation ... "gold standard" disease test known as spirometry, which shows ... the amount of air they can exhale and how ...
(Date:5/22/2013)... New research from Brigham and Women,s Hospital (BWH) finds ... uncommon but deadly lung disease, may be effective in ... findings will be presented at the American Thoracic Society ... New England Journal of Medicine on May 22 ... edition., "While this variant of the MUC5B gene is ...
(Date:5/22/2013)... ATS 2013, PHILADELPHIA ─More than 40 percent of ... funded clinic did not have the disease, researchers ... diagnostic "gold standard" for chronic obstructive pulmonary disease. ... the under-diagnosis of COPD, there has not been ... of over-diagnosis," said Christian Ghattas, MD., MSc, ...
(Date:5/22/2013)... In the past decade, more ... courts with donated uniforms, shoes, balls and other ... to partnering with manufacturers to provide youth with sporting ... $8.8 million in sports and fitness equipment over 10 ... outfitted for physical activity. , An inaugural donation ...
(Date:5/22/2013)... Alabama (PRWEB) May 22, 2013 ... solutions to state Health and Human Services and ... of Mental Health (ADMH) selected the CoCENTRIX ... platform to manage the Health Records and coordinate ... psychiatric hospitals. , CoCENTRIX is transitioning the ...
Breaking Medicine News(10 mins):Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3
... salon to help San Diego,s frantic families rid themselves of lice ... the head lice helpers, ( www.hairfairies.com ) today announced that it ... San Diego on May 12, 2009. , , ... salon dedicated to removing head lice. With salons in New ...
... May 12 Blue Cross and Blue Shield of ... an accreditation status of "Excellent" for its HMO products ... is an independent, non-profit organization that evaluates how well ... system -- physicians, hospitals, other providers and administrative services ...
... Manage Their Daily and Weekly MedicationsLAWRENCE, Mass., May 12 ... healthcare industry as a whole, it,s individual healthcare professionals ... a smaller scale.Goss, a medical technologist, enjoys her line ... good about what I do in the hospital lab," ...
... N.H., May 12 After very successful test marketing ... has begun selling its all-natural sports mints called Muscle ... and several electrolytes in a chewable mint, it is ... ingredients are used, and this is reflected in its ...
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... Evidence-based, Unbiased Determinations Use Latest Clinical InformationLANSDALE, Penn., ... today equals 17 percent of the U.S. gross ... will equal 20 percent. Most politicians and healthcare ... inefficiencies, inflated prices, poor management and waste that ...
Cached Medicine News:Health News:Lice Removal Salon Offers San Diego an Upscale Solution to an Undesirable Problem 2Health News:NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia 2Health News:Healthcare Professional Is Working to Make a Difference, One Dose at a Time 2Health News:New Class of Sports Nutrition Product Launched 2Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:IROs Help Cut Health Plan Costs During the Recession 2
... the serum tube is specially coated with ... coagulation process. Serum / gel tubes contain ... the tube; during centrifugation, this gel forms ... the blood cells. In the primary tube ...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
Medicine Products: